Abbott Laboratories (NYSE: ABT | ABT Price Prediction) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally different healthcare bets. Abbott delivered steady 6.9% ...
GLP-1 drugs such as Ozempic and Mounjaro are a revolution, not a trend. These weight loss drugs are one of the hottest markets in healthcare, and there’s been a dramatic surge in the number of ...
Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity. GLP-1 receptor ...
Mon, December 8, 2025 at 2:21 PM UTC Abbott's medical device segment grew 14.8% to $5.45 billion. The cardiovascular portfolio drove results, with TriClip for tricuspid valve repair gaining Japan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results